ArticleEJNMMI radiopharmacy and chemistry2025
Optimization of a GMP-compliant automated one-pot synthesis of Al[
Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial infections and antimicrobial resistance constitute significant threats to global human health, resulting in millions of fatalities annually. The development of innovative diagnostic agents is essential to facilitate precision medicine approaches in the battle against infectious diseases. Infection imaging using radiolabeled antimicrobial peptides (AMP) has emerged as a promising approach to detect bacterial infections. UBI(29–41), an AMP fragment, exhibits binding to bacterial cell membranes. Conjugated to chelators, UBI(29–41) has been labeled with radiometals such as 99mTc or 68Ga, and proven its ability to differentiate between sterile inflammation and infection with S. aureus by imaging. Due to its physical properties, 18F is more favorable for PET/CT imaging. As peptide labeling with 18F is challenging, we here implemented the Al18F labeling approach. This study aims to develop an optimized, fully automated, GMP-compliant process for radiolabeling of NOTA-conjugated UBI(29–41) with Al18F for PET/CT imaging of infections.
resultsOptimized reaction conditions led to the establishment of a robust Al18Fcomplexation protocol, which was implemented on a SynChrom R&D module. The labeling reaction was carried out in an acidic medium (pH 4.0) at 105 °C for 15 min, followed by a two-step HPLC purification for 20 min. Optimization of reagent concentrations enabled an activity yield up to 10 ± 1 GBq, with a radiochemical yield of 24.2 ± 0.6% and an apparent molar activity of 45 ± 4 GBq/µmol at end of synthesis (EOS) (n = 3). The radiochemical purity was 96.6 ± 0.3% as determined by analytical HPLC, using UV absorption (220 nm). Quality control was successfully established using validated analytical procedures.
conclusionsThe developed GMP-compliant radiolabelling process yields reproducible results with sufficient activities for further translation and investigations of clinical PET/CT imaging using Al[18F]F-NOTA-UBI(29–41) in infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.